{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(2)"],"submitter":["Unglaub JM"],"pubmed_abstract":["<h4>Abstract</h4>The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating phys"],"journal":["Blood advances"],"pagination":["375-385"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11787451"],"repository":["biostudies-literature"],"pubmed_title":["Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML."],"pmcid":["PMC11787451"],"pubmed_authors":["Kraus S","Sauer T","Einsele H","Pabst C","Dreger P","Renders S","Bornhauser M","Krause SW","Kauer J","Zukunft S","Middeke JM","Muller-Tidow C","Kramer M","Luft T","Unglaub JM","Schlenk RF","Rollig C","Schliemann C","Katelari E"],"additional_accession":[]},"is_claimable":false,"name":"Venetoclax-based salvage therapy as a bridge to transplant is feasible and effective in patients with relapsed/refractory AML.","description":"<h4>Abstract</h4>The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with hypomethylating agents has been approved for first-line treatment of patients with acute myeloid leukemia (AML) ineligible for intensive treatment. VEN-containing treatment strategies may also be effective in relapsed/refractory (R/R) AML; however, comparative studies with conventional therapies for fit patients as a bridge-to-transplant strategy are limited. Using propensity score matching (PSM), we compared 37 patients with R/R AML, who received VEN-based salvage therapy as bridge to allogeneic hematopoietic stem cell transplantation (allo-HCT), with 90 patients from the German Study Alliance Leukemia AML registry, who were treated with non-VEN-containing salvage therapy according to their treating phys","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jan","modification":"2026-06-01T10:26:18.728Z","creation":"2025-04-04T13:11:30.696Z"},"accession":"S-EPMC11787451","cross_references":{"pubmed":["39293081"],"doi":["10.1182/bloodadvances.2024013086"]}}